# US 2013/0157990 A1 · Method of drug detoxification > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0157990 A1 - Document ID: US20130157990A1 - Status: Published application - Kind: A1 - Application number: 13/771,602 - Filed: 2013-02-20 - Published: 2013-06-20 - Earliest claimed: 2010-08-20 - Assignees: Eagle Advancement Institute LLC - Inventors: James W. Carpenter; Ricardo D. Borrego - Web page: https://patentgrep.com/patent/US20130157990A1 ## CPC - A61K 31/485: Morphinan derivatives, e.g. morphine, codeine - A61K 31/05: Phenols {(cannabinoids A61K31/658)} - A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} - A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol - A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid - A61K 31/195: having an amino group - A61K 31/215: of carboxylic acids - A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine - A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil - A61K 31/403: condensed with carbocyclic rings, e.g. carbazole - A61K 31/404: Indoles, e.g. pindolol - A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin - A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine - A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine - A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin - A61K 31/426: 1,3-Thiazoles - A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline - A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) - A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof - A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine - A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine - A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) - A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam - A61K 31/551: having two nitrogen atoms, e.g. dilazep - A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine} - A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam - A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A method of detoxifying a patient addicted to at least one drug comprises the step of administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient. The method further comprises the step of administering an anesthetic component to the patient for putting the patient in a sedated state. The method further comprises the step of administering a detoxification component to the patient for detoxifying the patient of the drug(s) while the patient is in the sedated state. The detoxification component can comprise naloxone. The method further comprises the step of administering a second-medication component to the patient for further mitigating drug withdrawal symptoms of the patient while the patient is in the sedated state. The second-medication component can comprise naltrexone. The method further comprises the step of terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state. ## Claims ### Claim 1 A method of detoxifying a patient addicted to at least one drug, said method comprising the steps of: administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient; administering an anesthetic component to the patient for putting the patient in a sedated state; administering a detoxification component to the patient for detoxifying the patient of the drug(s) while the patient is in the sedated state; administering a second-medication component to the patient for further mitigating drug withdrawal symptoms of the patient while the patient is in the sedated state; and terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state; wherein the first-medication component comprises gabapentin, ropinirole, citric acid sodium citrate, famotidine, glycopyrrolate, ondansetron, dexamethasone, midazolam, or combinations thereof. ### Claim 2 (depends on 1) A method as set forth in claim 1 wherein the patient is in the sedated state for a period of time less than about four hours. ### Claim 3 (depends on 1) A method as set forth in claim 1 wherein the first-medication component comprises gabapentin, ropinirole, citric acid sodium citrate, famotidine, glycopyrrolate, ondansetron, dexamethasone, and midazolam. ### Claim 4 (depends on 1) A method as set forth in claim 1 wherein the first-medication component is administered prior to the administration of the anesthetic component. ### Claim 5 (depends on 1) A method as set forth in claim 1 wherein the anesthetic component comprises propofol. ### Claim 6 (depends on 1) A method as set forth in claim 1 wherein the detoxification component comprises naloxone. ### Claim 7 (depends on 6) A method as set forth in claim 6 wherein the detoxification component further comprises ketorolac, methacarbamol, dolasetron, trimethobenzamide, or combinations thereof. ### Claim 8 (depends on 1) A method as set forth in claim 1 wherein the second-medication component comprises naltrexone, clonidine, or combinations thereof. ### Claim 9 (depends on 1) A method as set forth in claim 1 wherein the second-medication component comprises naltrexone. ### Claim 10 (depends on 9) A method as set forth in claim 9 wherein a first portion of the naltrexone is administered intravenously and a second portion of the naltrexone is administered intramuscularly. ### Claim 11 (depends on 1) A method as set forth in claim 1 further comprising the step of administering a third-medication component to the patient after terminating administration of the anesthetic component to the patient for further mitigating drug withdrawal symptoms of the patent. ### Claim 12 (depends on 11) A method as set forth in claim 11 wherein the third-medication component comprises clonidine, naltrexone, promethazine, phenobarbital, ropinirole, ondansetron, or combinations thereof. ### Claim 13 (depends on 11) A method as set forth in claim 11 further comprising the step of administering a fourth-medication component to the patient after administration of the third-medication component to the patient for further mitigating drug withdrawal symptoms of the patent. ### Claim 14 (depends on 13) A method as set forth in claim 13 wherein the fourth-medication component comprises gabapentin, dicyclomine, prochlorperazine, haloperidol, benzotropine, carisoprodol, diazepam, triazolam, zolpidem, or combinations thereof. ### Claim 15 (depends on 1) A method as set forth in claim 1 further comprising the step(s) of: i) monitoring vital signs of the patient at least while the patient is in the sedated state; and/or ii) ventilating the patient at least while the patient is in the sedated state. ### Claim 16 (depends on 1) A method as set forth in claim 1 further comprising the step(s) of: i) gathering patient information prior to administration of the first-medication component to the patient and/or after terminating administration of the anesthetic component to the patient; and/or ii) examining the patient before administration of the first-medication component to the patient and/or after terminating administration of the anesthetic component to the patient. ### Claim 17 (depends on 1) A method as set forth in claim 1 wherein the drug is an opiate. ### Claim 18 A method of detoxifying a patient addicted to at least one opiate, said method comprising the steps of: administering a first-medication component to the patient for mitigating opiate withdrawal symptoms of the patient; administering an anesthetic component comprising propofol to the patient for putting the patient in a sedated state; ventilating the patient at least while the patient is in the sedated state; monitoring vital signs of the patient at least while the patient is in the sedated state; administering a detoxification component comprising naloxone to the patient for detoxifying the patient of the opiate(s) while the patient is in the sedated state; administering a second-medication component comprising naltrexone to the patient for further mitigating opiate withdrawal symptoms of the patient while the patient is in the sedated state; terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state; administering a third-medication component to the patient after terminating administration of the anesthetic component to the patient for further mitigating opiate withdrawal symptoms of the patent; and administering a fourth-medication component to the patient after administration of the third-medication component to the patient for further mitigating drug withdrawal symptoms of the patent. ### Claim 19 (depends on 18) A method as set forth in claim 18 wherein the first-medication component comprises gabapentin, ropinirole, citric acid sodium citrate, famotidine, glycopyrrolate, ondansetron, dexamethasone, midazolam, or combinations thereof. ### Claim 20 (depends on 19) A method as set forth in claim 19 further comprising the step(s) of: i) gathering patient information before administration of the first-medication component to the patient and/or after terminating administration of the anesthetic component to the patient; and/or ii) examining the patient before administration of the first-medication component to the patient and/or after terminating administration of the anesthetic component to the patient.